Tetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call
August 01 2019 - 7:00AM
Business Wire
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on commercializing novel
tetracyclines to treat serious and life-threatening conditions,
today announced that company management will host a conference call
at 4:30 p.m. ET on Thursday, August 8, 2019 to discuss the
Company’s second quarter 2019 financial results and provide a
general corporate update.
The conference call may be accessed by dialing 844-831-4023
(U.S. and Canada) or 731-256-5215 (international) and entering
conference ID number 2336585. A live audio webcast of the
conference call will be available online from the “Investors –
Events & Presentations” section of the Tetraphase website at
www.tphase.com.
A replay of the conference call will be available from 7:30 p.m.
ET on Thursday, August 8, 2019, through 7:30 p.m. ET on Thursday,
August 15, 2019 by dialing 855-859-2056 (U.S. and Canada) and
404-537-3406 for (international) callers. The conference ID number
is 2336585. A replay of the webcast will be available by visiting
Tetraphase’s website.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company
using its proprietary chemistry technology to create novel
tetracyclines for serious and life-threatening conditions,
including infections caused by many of the multidrug-resistant
bacteria highlighted as urgent public health threats by the World
Health Organization and the Centers for Disease Control and
Prevention. The Company has created more than 3,000 novel
tetracycline compounds using its proprietary technology platform.
Tetraphase's lead product XERAVA™ is approved for the treatment of
complicated intra-abdominal infections by the U.S. Food and Drug
Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are Phase 2 ready,
and TP-2846, which is in preclinical testing for acute myeloid
leukemia. The Company intends to outlicense its pipeline
candidates. Please visit www.tphase.com for more company
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190801005035/en/
Media and Investor Contact: Argot Partners Maeve
Conneighton 212-600-1902 maeve@argotpartners.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024